May 17, 2023
By Dr. Robert Popovian, Erin Delaney, and Dr. Michael Mandel We may be on the verge of a titanic shift in how drug prices are set. It’s been led by a dramatic decline in insulin prices, but it’s spreading to other brand drugs as well. This new paradigm is the...
May 16, 2023
By MacKay Jimeson Some of the most exciting advances in science and medicine are happening in Alzheimer’s, a disease that is one of the greatest epidemics of this generation. Eli Lilly announced promising results last week for experimental amyloid-targeting drug...
May 3, 2023
By MacKay Jimeson Drug shortages can be a matter of life and death. Sometimes, a shortage may simply require patients to temporarily pay a higher price or shop around to different local pharmacies to find one that has their prescription in stock. But, in the worst...
Apr 2, 2023
by MacKay Jimeson There is an interagency cold war between the Food and Drug Administration and the Centers for Medicare and Medicaid Services at the Department of Health and Human Services. FDA wants to approve promising treatments for patients faster. CMS...
Mar 20, 2023
By MacKay Jimeson In a proclamation last year, President Joe Biden said, “in the next 30 years, the number of Americans with Alzheimer’s is expected to reach nearly 14 million, straining families and our health care system. Fortunately, we are on the cusp of...
Jul 26, 2021
By Robert Popovian & Mark Atalla July 16, 2021 Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003. While there has been significant discussion about aducanumab’s...
